Share Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens Berman

PRNewsWire · CADL · November 19, 2026

Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens Berman

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: PRNewsWire ↗